- Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
- Actym Therapeutics Appoints Thomas Smart as CEO
- Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
- Precigen Reports Full Year 2023 Financial Results and Business Updates
- Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
- Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
- Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
On Wednesday, Precigen Inc (PGEN:NSQ) closed at 1.40, -25.53% below its 52-week high of 1.88, set on Aug 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.34 |
---|---|
High | 1.46 |
Low | 1.31 |
Bid | 1.39 |
Offer | 1.40 |
Previous close | 1.32 |
Average volume | 668.68k |
---|---|
Shares outstanding | 248.92m |
Free float | 216.24m |
P/E (TTM) | -- |
Market cap | 328.57m USD |
EPS (TTM) | -0.3933 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼